RESEARCH

Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials

OPEN ACCESS

Bianca Hemmingsen *PhD student*¹, Søren S Lund *physician*², Christian Gluud *chief physician and head of department*¹, Allan Vaag *professor*³, Thomas Almdal *chief physician and head of department*², Christina Hemmingsen *research assistant*¹, Jørn Wetterslev *chief physician*¹

¹Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; ²Steno Diabetes Center, Gentofte, Denmark; ³Department of Endocrinology, Rigshospitalet, Copenhagen University Hospital

Abstract

Objective To assess the effect of targeting intensive glycaemic control versus conventional glycaemic control on all cause mortality and cardiovascular mortality, non-fatal myocardial infarction, microvascular complications, and severe hypoglycaemia in patients with type 2 diabetes.

Design Systematic review with meta-analyses and trial sequential analyses of randomised trials.

Data sources Cochrane Library, Medline, Embase, Science Citation Index Expanded, LILACS, and CINAHL to December 2010; hand search of reference lists and conference proceedings; contacts with authors, relevant pharmaceutical companies, and the US Food and Drug Administration.

Study selection Randomised clinical trials comparing targeted intensive glycaemic control with conventional glycaemic control in patients with type 2 diabetes. Published and unpublished trials in all languages were included, irrespective of predefined outcomes.

Data extraction Two reviewers independently assessed studies for inclusion and extracted data related to study methods, interventions, outcomes, risk of bias, and adverse events. Risk ratios with 95% confidence intervals were estimated with fixed and random effects models.

Results Fourteen clinical trials that randomised 28 614 participants with type 2 diabetes (15 269 to intensive control and 13 345 to conventional control) were included. Intensive glycaemic control did not significantly affect the relative risks of all cause (1.02, 95% confidence interval 0.91 to 1.13; 28 359 participants, 12 trials) or cardiovascular mortality (1.11, 0.92 to 1.35; 28 359 participants, 12 trials). Trial sequential analyses rejected a relative risk reduction above 10% for all cause mortality and showed insufficient data on cardiovascular mortality. The risk of non-fatal

myocardial infarction may be reduced (relative risk 0.85, 0.76 to 0.95; $P=0.004$; 28 111 participants, 8 trials), but this finding was not confirmed in trial sequential analysis. Intensive glycaemic control showed a reduction of the relative risks for the composite microvascular outcome (0.88, 0.79 to 0.97; $P=0.01$; 25 600 participants, 3 trials) and retinopathy (0.80, 0.67 to 0.94; $P=0.009$; 10 793 participants, 7 trials), but trial sequential analyses showed that sufficient evidence had not yet been reached. The estimate of an effect on the risk of nephropathy (relative risk 0.83, 0.64 to 1.06; 27 769 participants, 8 trials) was not statistically significant. The risk of severe hypoglycaemia was significantly increased when intensive glycaemic control was targeted (relative risk 2.39, 1.71 to 3.34; 27 844 participants, 9 trials); trial sequential analysis supported a 30% increased relative risk of severe hypoglycaemia.

Conclusion Intensive glycaemic control does not seem to reduce all cause mortality in patients with type 2 diabetes. Data available from randomised clinical trials remain insufficient to prove or refute a relative risk reduction for cardiovascular mortality, non-fatal myocardial infarction, composite microvascular complications, or retinopathy at a magnitude of 10%. Intensive glycaemic control increases the relative risk of severe hypoglycaemia by 30%.

Introduction

Observational studies suggest an association between the extent of hyperglycaemia and the risk of death and of macrovascular and microvascular disease in patients with type 2 diabetes.¹⁻³ Three recent randomised clinical trials in patients with type 2 diabetes were not able to detect (or reject the possibility of) reduced cardiovascular disease or mortality with intensive compared with conventional glycaemic control.⁴⁻⁶ Worries arose as the results from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial in 2008 showed increased all cause

Correspondence to: B Hemmingsen bh@ctu.rh.dk

Extra material supplied by the author (see <http://www.bmj.com/content/343/bmj.d6898?tab=related#webextra>)

mortality and cardiovascular mortality in the intensive treatment group compared with conventional treatment.⁴ The increased mortality led to early termination of the ACCORD trial.⁴ On the other hand, randomised clinical trials have indicated a beneficial effect on microvascular complications of intensive versus conventional glycaemic control in patients with type 2 diabetes. However, inconsistencies exist among the trials with respect to which type of microvascular complications are prevented and the magnitude of the effect of intensive glycaemic control.⁵⁻⁸ The price of intensive glycaemic control may be an increased risk of hypoglycaemia. Achieving intensive glycaemic control in patients with type 2 diabetes requires enormous effort from the patient as well as resources from the healthcare system, particularly compared with the well documented beneficial effects of lipid and blood pressure lowering treatment.⁹

The definition of intensive glycaemic control varies among trials and guidelines. The ACCORD trial and the Veterans Affairs Diabetes Trial (VADT) used a target of glycated haemoglobin A_{1c} (HbA_{1c}) below 6.0% for intensive glycaemic control compared with a target of HbA_{1c} below 6.5% in the Action in Diabetes and Vascular Disease—Preterax and Diamicon Modified Release Controlled Evaluation (ADVANCE) trial. The results from these trials have created a debate about the optimal choice of glycaemic target. The American Diabetes Association recommends an HbA_{1c} level of less than 7.0% as the standard glycaemic treatment goal, whereas the International Diabetes Federation recommends a level of less than 6.5%.¹⁰⁻¹²

In our published protocol, we predefined inclusion of all trials comparing patients treated to a specific target for intensive glycaemic control with patients treated to a conventional but higher glycaemic target.¹³ The difference in treatment strategy between the groups was clearly defined either as values of HbA_{1c} or as intensifying glycaemic control. The intensive glycaemic targets varied across the trials, but the trials compared the results of trying to achieve a distinct lower target with those of aiming for a higher one. We believe that the existence of a “gold threshold” target remains to be established and that the hypothesis so far has been that targeting/lowering the HbA_{1c} may have a beneficial effect along the entire scale of measurements of HbA_{1c} unless hypoglycaemia is reached. In this sense, we have included all trials comparing an intensified glycaemic target with a more “relaxed” glycaemic target, often reflecting usual clinical practice for a given place and time.

This systematic review reanalyses current evidence of the effect of targeting intensive glycaemic control on all cause mortality, cardiovascular mortality, cardiovascular disease, and microvascular disease in patients with type 2 diabetes. We consider the effects of intensive glycaemic control irrespective of differences among trials in individual targets or achieved glycaemic control.¹³

As well as assessing the effect of intensive glycaemic control on the outcomes reported in this systematic review (all cause mortality, cardiovascular mortality, non-fatal myocardial infarction, composite microvascular complications, retinopathy, and nephropathy), we assessed macrovascular complications as a composite outcome, non-fatal stroke, peripheral and cardiac revascularisation, retinal photocoagulation, end stage renal disease, congestive heart failure, adverse events, the cost of the intervention, and quality of life. The results for these supplemental outcomes are published elsewhere.¹⁴

Methods

This review follows the recommendations of the Cochrane Collaboration.¹⁵ It is based on our published Cochrane protocol.¹³

We included all randomised trials that compared the targeting of intensive glycaemic versus conventional glycaemic control in patients with type 2 diabetes.^{13 14} We analysed trials according to the setting of the intensive glycaemic intervention. We analysed trials of targeting intensive glycaemic control in patients without acute events at entry or without concomitant treatments targeting other cardiovascular risk factors as “trials exclusively dealing with glycaemic control in usual care setting.”¹³ The data in the review reported here are from this group of trials, representing 28 614 (95%) of 29 986 participants included in our review.^{13 14} We excluded three trials assessing multimodal interventions,¹⁶⁻¹⁸ as well as three trials assessing intensive glycaemic control as part of an acute intervention.¹⁹⁻²¹ For the vast majority of estimated effects of intervention, these exclusions did not cause noticeable changes.¹³

We analysed trials of targeting intensive glycaemic control as part of an acute intervention and trials with multimodal interventions separately.^{13 14} We also did an overall meta-analysis combining data from all included trials irrespective of the setting in which intensive glycaemic control was applied.^{13 14} We refer only to data from the analyses of trials exclusively dealing with glycaemic control in usual care setting in this paper, but the Cochrane version gives a full presentation.¹⁴

Search strategy

We did a search in the Cochrane Library, Medline, Embase, Science Citation Index Expanded, LILACS, and CINAHL in December 2010 for randomised clinical trials of targeting intensive glycaemic control versus targeting conventional glycaemic control in patients with type 2 diabetes. Web appendix 1 describes the search terms and strategies for each database. We also searched abstracts presented at the American Diabetes Association and European Association for the Study of Diabetes congresses. We contacted relevant drug companies and the US Food and Drug Administration for unpublished randomised trials relevant to our review. We searched reference lists of included trials and (systematic) reviews, meta-analyses, and health technology assessment reports. We did internet searches for all trials to find additional information about the included trials. We contacted authors for information about additional trials.

Study selection

Two authors (BH and AV, CG, CH, SSL, or TA) independently screened titles and abstracts according to the inclusion criteria. We included a trial if it was a randomised clinical trial, compared targeting intensive glycaemic control versus targeting conventional glycaemic control, and was done in patients with type 2 diabetes. We included trials irrespective of duration, language, publication status, or predefined outcomes.

Data extraction and risk of bias assessment

Two authors (BH and CH or TA) independently extracted information from each included trial by using standard data extraction forms and assessed the risk of bias as advised in the Cochrane Handbook of Systematic Reviews of Interventions.¹⁵ We assessed the following risk of bias domains: sequence generation, concealment of allocation, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias.¹⁵ We classified each domain as adequate, unclear, or

inadequate. Web appendix 2 gives details. Discrepancies between authors' assessments were resolved by involvement of a third author (JW). Translators extracted data from all relevant non-English articles.

We extracted data on several baseline characteristics of the participants (such as age, duration of disease, HbA_{1c}) and outcomes. The predefined outcomes reported in this review are all cause mortality, cardiovascular mortality, non-fatal myocardial infarction, microvascular disease reported as a composite outcome, retinopathy, nephropathy, and severe hypoglycaemia.¹³ We sought any relevant missing information from the original author(s) of the randomised trial.

When we identified more than one publication of an original trial, we assessed these together to maximise data collection. In case of substantial disagreements between older and newer publications, we contacted the authors.

Statistical analysis

We used Review Manager version 5.0.25 for statistical analysis.²² We summarised data on all cause mortality, cardiovascular mortality, non-fatal myocardial infarction, and severe hypoglycaemia statistically as relative risks with 95% confidence intervals. We used both a random effects model and a fixed effect model.^{23 24} In case of discrepancy between the two models, we report both results; otherwise, we report the random effects model.

We examined heterogeneity with the I² statistic, quantifying the proportion of between trial variance to the sum of the between trial variance and a common sampling error.²⁵ We graded values of I² between 0% to 40% as "heterogeneity might not be important," values between 30% and 60% as "moderate heterogeneity," values between 50% and 90% as "substantial heterogeneity," and values between 75% and 100% as "considerable heterogeneity."²⁵ When we found heterogeneity, we attempted to determine potential reasons by examining characteristics of individual trials.

We did subgroup analyses stratifying trials according to risk of bias, length of study, diagnostic criteria for type 2 diabetes, language of publication, and source of funding for all cause mortality, cardiovascular mortality, and non-fatal myocardial infarction.

We did trial sequential analyses.^{26 27} This is similar to interim analyses in a single trial, where monitoring boundaries are used to decide whether a trial could be terminated early when a P value is sufficiently small to show the anticipated effect. Because no reason exists why the standards for a meta-analysis should be less rigorous than those for a single trial, analogous trial sequential monitoring boundaries can be applied to meta-analysis.²⁸⁻³⁰ Cumulative meta-analyses of trials are at risk of producing random errors because of sparse data and repetitive testing of accumulating data when the required information size (analogous to the sample size of an optimally powered clinical trial) has not been met. Trial sequential analysis depends on the quantification of the required information size (the meta-analysis sample size). In this context, the smaller the required information size the more lenient the trial sequential monitoring boundaries are and, accordingly, the more lenient the criteria for statistical significance will be. We calculated a heterogeneity (I²) adjusted required information size. We did the trial sequential analyses with an intention to maintain an overall 5% risk of a type I error, which is the standard in most meta-analyses and systematic reviews. On the basis of pre-determined criteria,¹³ we initially calculated the required information size to detect or reject an intervention effect of a 10% relative risk reduction with a risk

of a type II error of 20% (power of 80%). We chose a 10% relative risk reduction equivalent to a number needed to treat of approximately 100 patients, because even this decrease in mortality is likely to be clinically meaningful. For severe hypoglycaemia, however, we chose a 30% increase in relative risk equivalent to a number needed to harm of 50. We also provide the 95% confidence intervals adjusted for sparse data and repetitive testing, which we describe as the trial sequential analysis adjusted 95% confidence intervals. We used TSA version 0.9 beta (www.ctu.dk/tsa) for these analyses.

Results

Results of the search and trial, participant, and intervention characteristics

Figure 1⇓ summarises the results of the search. We excluded 42 references after further evaluation. The main reasons for exclusion were that the trial was not randomised (11 references),³¹⁻⁴¹ participants were not patients with type 2 diabetes or we could not separate data on patients with type 2 diabetes (four references),⁴²⁻⁴⁵ or no predefined differences in glycaemic intervention target existed (16 references).⁴⁶⁻⁶¹ In addition, we excluded trials that assessed intensive glycaemic control as a part of an acute intervention (five references, three trials) or had concomitant targeting of several cardiovascular risk factors in the glycaemic intervention arm (six references, three trials).^{16-21 62-66} Table 1⇓ gives a list of excluded trials.

We included 20 randomised trials, of which 14 exclusively dealt with glycaemic control in the usual care setting in patients without acute events at entry.^{4-8 67-111} Thirteen of the trials were published in English and one in Russian.⁸⁵ The 14 included trials were described in 51 publications. We noted a discrepancy in the number of participants in two publications of one trial.^{83 84} We used baseline data from the publication in the *Netherlands Journal of Medicine*.⁸³

The trials included 28 614 participants, of whom 15 269 were randomised to intensive glycaemic control and 13 345 to conventional glycaemic control. Table 2⇓ shows key characteristics of the included trials, and table 3⇓ shows characteristics of trials' participants. The included trials were mainly done in North America and Europe. The number of randomised patients in each trial ranged from 20 to 11 140.^{5 87} All 14 included trials were randomised clinical trials.

Two of the trials had a factorial design.^{4 5} The UK Prospective Diabetes Study (UKPDS) had a substudy in which some of the participants were randomised to intensive blood pressure control versus conventional blood pressure control.¹⁰² The University Group Diabetes Program (UGDP) randomised participants to five different treatment regimens.⁸⁸ We chose to report the "insulin variable" group as the intensive group and the "insulin standard" group as the conventional group.

The Kumamoto trial had a planned length of intervention of six years.⁷ Only two of the included 110 participants changed their glycaemic intervention regimen after the predefined intervention period. The trial therefore continued on the initiative of the participants. We have reported all outcomes in this analysis after 10 years of follow-up, except for severe hypoglycaemia (reported after eight years of follow-up).⁹⁵

Ten trials described how the diagnosis of type 2 diabetes was established (see web appendix 3).^{4 6-8 82 83 87 88 92 106} Four trials did not describe how the diagnosis was established.^{5 85 86 94} Most exclusion criteria consisted of liver disease, kidney disease, or other severe concurrent illnesses.

The anti-diabetes interventions used in the trials often included add-on regimens consisting of several oral drugs. If participants could not reach the glycaemic target with these regimens, insulin was started. The usual add-on regimen was identical in the intensive and conventional intervention groups of the single trials, except in the ADVANCE trial and the Rational Effective Multicomponent Therapy in the Struggle Against Diabetes Mellitus in Patients With Congestive Heart Failure (REMBO) trial, in which participants targeting intensive glucose control were given gliclazide.^{5 85} Most trials allowed combination of oral anti-diabetes interventions and insulin. Two trials allowed only monotherapy (insulin) in both the intensive intervention group and conventional intervention group.^{7 88}

The treatment targets for glycaemic control varied between trials in both the intensive treatment group and the conventional treatment group (table 2). The ACCORD trial and the VADT had the lowest target for HbA_{1c} in the intensive intervention groups (both less than 6%).^{4 6} Some of the trials did not predefine the glycaemic target in values of HbA_{1c} but used fasting glucose concentration as a target for treatment.^{8 83 86 88 94}

Bias risk assessment

We divided the trials into those with a low risk of bias and those with a high risk of bias on the basis of assessment of sequence generation, concealment of allocation, and blinding according to the Cochrane Handbook risk of bias tool.¹⁵ When we judged all three domains to have a low risk of bias, we designated the trial as having a low risk of bias. Table 4 reports the bias risk assessments of the included trials. We considered six trials to have a low risk of bias.^{4 6 8 88 92}

Clinical outcomes

All cause mortality

Twelve trials provided information on all cause mortality in a total of 28 359 participants (fig 2). Meta-analysis showed no significant effect of intensive glycaemic control (relative risk 1.02, 95% confidence interval 0.91 to 1.13; P=0.74; 28 359 participants, 12 trials) compared with conventional glycaemic control. Heterogeneity was moderate (I²=30%; P=0.18).

Subgroup analyses of the trials according to risk of bias, length of study, diagnostic criteria for type 2 diabetes, and source of funding showed no statistically significant differences between subgroups (that is, no significant interaction). Subgroup analyses for language of publication could not be done.

Trial sequential analysis showed that only 28 149 of the heterogeneity adjusted required information size of 46 677 patients were accrued. The cumulative Z curve did not cross any boundaries for benefit or harm (trial sequential analysis adjusted 95% confidence interval 0.88 to 1.18) (fig 3). However, the cumulative Z curve crossed the futility boundaries, suggesting that a relative risk reduction of 10% or greater could be rejected.

Cardiovascular mortality

Twelve trials provided information on cardiovascular mortality and were included in the analyses. Web appendix 3 gives details of the definitions and reporting of cardiovascular mortality in the trials. The meta-analysis of the 12 trials did not show a statistically significant effect of the intervention on cardiovascular mortality (relative risk 1.11, 0.92 to 1.35; P=0.27; 28 359 participants, 12 trials). Figure 4 shows the forest plot analysis of cardiovascular mortality. Heterogeneity was present (I²=46%; P=0.08).

Subgroup analyses of the trials according to risk of bias, length of study, and source of funding showed no statistically significant differences between subgroups. Subgroup analyses for language of publication could not be done. Including only trials that described the diagnostic criteria for type 2 diabetes changed the effect estimate to a significant value in favour of conventional glycaemic control (relative risk 1.26, 1.08 to 1.46; P=0.002; 17 093 participants, 9 trials). The test for interaction showed a statistically significant difference between the two estimates (P=0.001).

Trial sequential analysis showed that barely 22% of the heterogeneity adjusted required information size to detect or reject a 10% relative risk reduction was actually accrued (trial sequential analysis adjusted 95% confidence interval 0.70 to 1.76). None of the boundaries for benefit, harm, or futility was crossed, showing too little evidence to allow us to conclude whether the intervention was beneficial, harmful, or without any effect on this outcome (fig 5).

Non-fatal myocardial infarction

A total of 1237 non-fatal myocardial infarctions were recorded in 28 111 participants from eight trials. The details of how the diagnosis of myocardial infarction was defined varied among the trials (web appendix 3). The effect estimate showed a significant benefit of targeting intensive glycaemic control in a conventional meta-analysis (relative risk 0.85, 0.76 to 0.95; P=0.004; 28 111 participants, 8 trials). Heterogeneity was absent (I²=0%; P=0.70). Figure 6 shows the forest plot.

Subgroup analyses of the trials according to low risk of bias did not change the effect estimates. Meta-analysis of trials with a high risk of bias changed the effect estimate to a statistically non-significant value (relative risk 0.83, 0.23 to 2.98; P=0.78; 306 participants, 3 trials). A test for interaction showed no statistically significant difference in the effect estimates. We could not do the subgroup analyses for language of publication, duration of intervention, funding source, and diagnostic criteria owing to lack of data.

Trial sequential analysis showed a lack of sufficient evidence of a benefit of targeting intensive glycaemic control for the reduction of non-fatal myocardial infarction (trial sequential analysis adjusted 95% confidence interval 0.71 to 1.02). Only 27 958 (44%) of the heterogeneity adjusted required information size of 63 446 patients required to detect a 10% relative risk reduction for non-fatal myocardial infarction were accrued (fig 7).

Composite outcome of microvascular complications

We assessed a composite outcome of microvascular complications, consisting of manifestation and progression of nephropathy, end stage renal disease, manifestation and progression of retinopathy, and retinal photocoagulation. We could extract usable data from three trials that had a predefined composite microvascular outcome.^{4 5 8} The definitions of the reported composite outcome varied among the included trials (web appendix 2).

For the composite outcome of microvascular complications, we found a benefit of targeting intensive glycaemic control compared with targeting conventional glycaemic control (relative risk 0.88, 0.79 to 0.97; P=0.01; 25 600 participants, 3 trials) (fig 8). The I² statistic was 45% (P=0.16). We found an absolute risk reduction of about 1% (risk difference -0.01, 95% confidence interval -0.02 to 0.00; P=0.006). However, trial sequential analysis did not show sufficient evidence for a 10%

relative risk reduction for the composite outcome of microvascular complications (trial sequential analysis adjusted 95% confidence interval 0.76 to 1.01) (fig 9).

Retinopathy

Retinopathy was primarily reported with the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale (web appendix 3). The effect estimate showed significant benefit in favour of intensive glycaemic control (relative risk 0.80, 0.67 to 0.94; $P=0.009$; 10 793 participants, 7 trials) (fig 10). Heterogeneity was substantial ($I^2=59\%$; $P=0.02$). Trial sequential analysis showed a lack of sufficient evidence for a 10% or greater relative risk reduction in retinopathy (trial sequential analysis adjusted 95% confidence interval 0.54 to 1.17) (fig 11).

Nephropathy

The definition of nephropathy varied among trials (web appendix 3). We found no statistically significant effect of intensive glycaemic control on nephropathy (relative risk 0.83, 0.64 to 1.06; $P=0.13$; 27 769 participants, 8 trials) (fig 12). Heterogeneity was substantial ($I^2=75\%$, $P<0.001$).

Severe hypoglycaemia

The definition of severe hypoglycaemia varied among trials (web appendix 3). The ACCORD trial reported the number of hypoglycaemic events in two ways—requiring any assistance and requiring medical assistance. We have reported the number requiring any assistance, as this definition accords best with the definition in the other included trials.⁵ Five trials, besides the ACCORD trial, had the assistance of a third person as a part of their definition of serious hypoglycaemia.^{5 7 8 80 109}

Meta-analysis of intensive versus conventional control showed a statistically significant estimate of effect on severe hypoglycaemia (relative risk 2.39, 1.71 to 3.34; $P<0.001$; 27 844 participants, 9 trials). Heterogeneity was substantial ($I^2=73\%$, $P=0.005$) (fig 13).

For the application of trial sequential analysis to severe hypoglycaemia, the protocol assumed an increase in relative risk of 30%, equivalent to a number needed to harm of 50, to construct the trial sequential monitoring boundaries. The cumulative Z curve crossed the trial sequential monitoring boundary for harm, indicating that sufficient evidence exists for a 30% increase in relative risk of severe hypoglycaemia when intensive glycaemic control is targeted (fig 14).

Discussion

Our key finding is that whether the clinician is targeting an intensive or conventional glycaemic value does not seem to change the risk of all cause mortality or cardiovascular mortality. However, intensive glycaemic control might reduce the risk of non-fatal myocardial infarction, microvascular complications (on the basis of a composite outcome), and retinopathy. The risk of nephropathy does not seem to change with the glycaemic target. The price of intensive glycaemic control is an increased risk of severe hypoglycaemia. However, among these conclusions, only that for hypoglycaemia seems to be based on a sufficient information size at this stage. A reduced risk of microvascular disease with intensive versus conventional glucose control has been found in several individual trials and is consistent with findings in patients with type 1 diabetes. However, our meta-analysis suggests that data on microvascular outcomes in patients with type 2 diabetes are still insufficient. Absence of evidence cannot be taken as evidence of absence,

however, and an effect at the size of the point estimates found in our meta-analyses may eventually be shown when further trials are done.¹¹²

Strengths and limitations

This is the first and most comprehensive systematic review with meta-analyses of targeting intensive versus conventional glycaemic control in patients with type 2 diabetes that focuses on mortality and macrovascular as well as microvascular complications. The strengths of this review are a published protocol, a comprehensive search strategy, and rigid inclusion criteria for the randomised trials.¹³

We have included trials with large differences in the average duration of type 2 diabetes, length of the interventions, patients' age and risk of cardiovascular disease, and assessment of glycaemic control, as well as pre-specified targets of glycaemic control. We included trials irrespective of the language of publication and outcomes reported. Two authors independently extracted data and obtained data from or confirmed data with corresponding authors of the included trials.

Several meta-analyses have recently been published on this topic.¹¹³⁻¹²¹ However, many of the meta-analyses claiming to assess the effect of targeting intensive glycaemic control versus conventional glycaemic control have included trials on the basis of achieved (that is, during follow-up) rather than targeted (that is, as randomly allocated) differences in glycaemic control.^{113 115 116 120 121} For example, they included head to head comparisons of anti-diabetes drugs with a similar target of HbA_{1c} below 6.5% in both intervention groups, such as the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) trial of add-on pioglitazone versus placebo.⁵⁰ Boussageon et al applied the same approach in a recently published meta-analysis.¹¹³ This chosen strategy of selection is potentially problematic, as the levels of glycaemic control targeted and achieved in a clinical trial represent different chosen variables. To some extent, the achieved glycaemic control represents observational data precluding inferences about causality with respect to its influence on other outcomes. In contrast, target levels, as part of the randomised intervention strategy, can support inferences about causality. Therefore, to optimally assess the clinical effect of aiming for intensive glycaemic control, which is probably the relevant question for the clinician as well as people trying to establish evidence based guidelines, trials need to be meta-analysed primarily on the basis of predefined differences in glycaemic targets.

The previous meta-analyses that dealt exclusively with trials in which the patients were randomised to different glycaemic targets included only four to six trials.^{114 117-119} We included 14 trials, which is at least eight more trials than in the previous meta-analysis. All of the meta-analyses investigating the effect of targeting intensive glycaemic control have included the four major trials,^{4 5 6 8} which contributed the greatest number of the participants in our analysis (27 391 of 28 614 participants). However, none of the previous meta-analyses included trials published in languages other than English or tested for the risk of having false positive P values or unrealistically narrow confidence intervals. Furthermore, none of the previous meta-analyses was done as a Cochrane systematic review.¹⁵

The weaknesses of our analyses and conclusions mirror the weaknesses in the individual included trials. Most importantly, only six of the 14 trials included were classified as trials with a low risk of bias. However, we found no statistically significant association between the risk of bias and the effect estimates in subgroup analyses. Analysing cardiovascular mortality by

diagnostic criteria suggested a negative effect estimate for intensive versus conventional glycaemic control in the trials with a clear description of the diagnosis. However, analysis of trials describing diagnostic criteria excluded the ADVANCE trial, which is the largest trial included in this systematic review (11 140 participants, about one third of the total information size). Excluding the ADVANCE trial, which reported a neutral effect of intensive versus conventional glycaemic control on cardiovascular mortality, substantially increased the weight of some other trials in the analysis. This applies in particular to the ACCORD trial, which included a marginally lower number of participants than did the ADVANCE trial. Unlike the ADVANCE trial, the ACCORD trial reported an increased risk of cardiovascular death for targeting intensive versus conventional glycaemic control. Apart from diagnostic criteria, subgroup analyses for other variables supported the conclusions from the primary overall analysis. Given the somewhat arbitrary criteria for type 2 diabetes, the progressive nature of the disease, and, perhaps in particular, the inclusion of trials in this analysis with different glycaemic targets and clinical outcomes, we find it most likely that the reduced cardiovascular mortality with conventional glycaemic control of the subgroup analysis according to diagnostic criteria represents a chance finding, possibly arising from confounding by the ACCORD trial.

We evaluated the strength of the available evidence by comprehensive analyses of the risk of sparse data and repetitive testing with trial sequential analysis. We did this for outcomes that showed significance in the cumulative meta-analysis, calculating heterogeneity adjusted required information sizes and applying trial sequential monitoring boundaries of benefit, harm, and futility.^{26 27} The result of the trial sequential analysis rules out an effect of intensive glycaemic control on all cause mortality larger than a 10% reduction in relative risk. Even though the conventional meta-analyses of non-fatal myocardial infarction, composite microvascular complications, and retinopathy indicated a statistically significant effect estimate, trial sequential analysis showed that sufficient evidence was not yet available for a conclusion to be reached.

In addition to the differences between the glycaemic targets among the trials, the conventional treatment groups as well as the anti-diabetes interventions used to achieve the targets differed among the trials. Furthermore, the measurement used to assess the levels of glycaemic control varied among the included trials. Some trials defined the target glucose values by using blood glucose, providing only a “snapshot” of the overall glycaemic control. Most of the included trials expressed glycaemic control and glycaemic targets in values of HbA_{1c}, reflecting an average of the blood glucose concentration over several weeks. We were unable to evaluate the effects of the specific anti-diabetes drugs used to achieve the glycaemic targets. A wide range of glucose lowering interventions were used to achieve the glycaemic goal within and among the trials. In the ACCORD and the ADVANCE trials, a greater proportion of the participants randomised to intensive glycaemic control received rosiglitazone compared with the conventional treatment group.^{4 5} We have not been able to quantify any drug specific effects on our outcomes that may counteract or contribute to both benefits and harms of glycaemic control. The most suitable way to answer the specific question of whether the target in itself affects outcomes important to patients would be to include only trials that used one blood glucose lowering drug exclusively to receive a predefined glycaemic target. However, such a design would seem to be inapplicable to clinical practice.

The participants in the included trials represented a diverse population with type 2 diabetes. The results of our review should

be interpreted with this in mind. The diagnosis of type 2 diabetes varied among the trials, and some trials used a definition of type 2 diabetes that may have included participants with impaired glucose tolerance. Some of the trials included only participants with newly diagnosed type 2 diabetes, whereas others included patients with longer duration of type 2 diabetes. Participants' age, body mass index, glycaemic control, and duration of diabetes were in keeping with what might be expected in clinical practice. In spite of this, for several effects of the intervention on outcomes, we found no or only moderate heterogeneity. Furthermore, we found no significant subgroup differences when we stratified for the diagnostic criteria used for inclusion in the trials. Although we included a broad spectrum of patients with type 2 diabetes and, owing to potential selection bias—for instance, towards healthier and more motivated patients volunteering in a clinical trial compared with the background population of patients—saying how typical the participants in each clinical trial may be compared with the wider general population of patients with type 2 diabetes is difficult. On the other hand, the heterogeneity in this review might indeed reflect the well known heterogeneity in clinical practice.

The reporting of severe hypoglycaemia is problematic in several ways; first of all, the definitions of severe hypoglycaemia were diverse. Many of the trials included assistance from another person, without further specification. The grade of assistance from another person may vary from handing a juice to giving glucagon injections. In addition, the design of the included trials made blinding the participants impossible, which may in turn lead to reporting bias.¹⁵

Many of the included trials were not designed or powered to assess our predefined outcomes, which explains the insufficient data from these trials. Furthermore, for some outcomes only a few trials could provide data. This increases the risk of outcome measure reporting bias.¹⁵

Relation to other studies and reviews

The UGDP was the first “large scale,” multicentre clinical trial on the topic. It did not find any differences in mortality and cardiovascular outcomes between targeting intensive or conventional glycaemic control with insulin.⁸⁸ The much larger UKPDS also failed to show a benefit on mortality or cardiovascular outcomes for targeting intensive glycaemic control with insulin or a sulfonylurea.⁸ However, a small subgroup of 753 overweight patients randomly assigned to intensive glycaemic control with metformin showed a benefit of intensive glycaemic control.¹⁰⁰ Post hoc observational data from the UKPDS suggested that a 1% decrease in HbA_{1c} reduced the risk of non-fatal myocardial infarction by 14%.¹ A 10 year follow-up of the initial randomised groups in the UKPDS suggested long term beneficial effects of intensive glucose control on cardiovascular disease and mortality with both metformin and sulfonylurea-insulin regimens. Our analysis indicated a significant 15% reduction in relative risk of non-fatal myocardial infarction in favour of intensive glycaemic control. However, this was not confirmed when challenged for a 10% relative risk reduction in trial sequential analysis with adjustment for repetitive testing on accumulating and sparse data. A potential explanation for the magnitude of beneficial effects of lower glucose concentrations being more pronounced in observational studies than in randomised trials and prospective studies is the effects of confounding by indication in the observational studies.

Recently, two large trials attempted to answer the question of whether intensive glycaemic control is superior to conventional

glycaemic control.^{4 5} Worries arose as the results from the ACCORD trial in 2008 showed increased all cause mortality and cardiovascular mortality with intensive glycaemic control compared with conventional glycaemic control. The increased mortality led to early termination of the ACCORD trial. On the other hand, the ACCORD trial showed a reduction in the risk of non-fatal myocardial infarction with intensive glycaemic control. The question remains why the ACCORD trial reported increased mortality but a reduced risk of non-fatal myocardial infarction. Recently, data from the follow-up period, after termination of the intensive glycaemic intervention arm, have been published and reported that the increased risk of mortality and reduced risk of non-fatal myocardial infarction have persisted.¹²² Explanations for this finding have been sought by the authors of the ACCORD trial, but no firm evidence has been found.

Observational data from the UKPDS showed a 37% reduction in the risk of microvascular complications for each 1% decrease in HbA_{1c}.¹ The ADVANCE trial found a 14% relative risk reduction for major microvascular events when targeting intensive glycaemic control.⁷⁵ The UKPDS 33 showed a 25% risk reduction in microvascular outcomes when targeting intensive glycaemic control.⁸ We found a 12% relative risk reduction for the composite microvascular outcome. We found a 20% relative risk reduction for retinopathy in favour of intensive glycaemic control. The absolute risk reduction was 3%.

The Kumamoto trial showed a pronounced reduction in the incidence of nephropathy in both the primary prevention cohort (11.5% v 43.5%) and the secondary intervention cohort (16% v 40%) when targeting intensive glycaemic control.⁷ The ADVANCE trial showed a 21% relative risk reduction for nephropathy when targeting intensive glycaemic control, whereas this could not be shown in ACCORD.^{5 74} We found no significant effect of glycaemic intervention on the risk of nephropathy.

Microvascular data from the ACCORD trial and the UKPDS indicate that the beneficial effects of intensive glycaemic control on microvascular disease take more than about five years to emerge or that the benefits on microvascular disease achieved by intensive glycaemic control are less pronounced for patients with advanced type 2 diabetes (ACCORD) than for patients with new onset of type 2 diabetes (UKPDS).^{8 74} On the other hand, the meta-analysis of retinopathy indicated that patients with more advanced stages of type 2 diabetes (ACCORD, VADT) might benefit more from intensive glycaemic control than do patients newly diagnosed as having type 2 diabetes (UKPDS, UGDP).^{6 8 74 91}

We identified severe hypoglycaemia as a serious adverse effect strongly associated with intensive glucose control, which seems to be in accordance with established knowledge and other meta-analyses.^{114 116 117} We did not have access to trial data at the level of the patient, so we could not explore whether an association exists between severe hypoglycaemic events and the risk of sudden unexpected death.

In January 2010 the American Diabetes Association published a guideline recommending an HbA_{1c} goal of less than 7% to reduce microvascular complications.¹⁰ Treatment targets of HbA_{1c} at 7% have been used in only three trials exclusively dealing with glycaemic control in usual care setting, and they are all of relatively small sample size, consisting in total of 234 participants.^{7 82 85} Only one of these trials had a duration of more than one year.⁷

Conclusion

We found evidence to refute the suggestion that intensive compared with conventional glycaemic control reduces all cause mortality with a relative risk reduction of 10% or more. We found insufficient information to confirm or exclude a 10% relative risk reduction in cardiovascular mortality and non-fatal myocardial infarction with intensive glycaemic control. We found insufficient evidence for a reduction in risk of composite microvascular complications, retinopathy, and nephropathy. Conversely, we confirmed a 30% increase in relative risk of severe hypoglycaemia with intensive compared with conventional glycaemic control. Accordingly, treatment and choice of a glycaemic target for patients with type 2 diabetes need to take both harms and benefits into account.

We thank Bern Richter and the Cochrane Metabolic and Endocrine Disorders Group for valuable assistance. We thank Sarah Klingenberg, trials search co-ordinator of the Cochrane Hepato-Biliary Group, for her assistance in developing the search strategy. Thanks to Dimitrinka Nikolova from the Cochrane Hepato-Biliary Group for advising during the writing process and for translating and extracting data from a Russian article. We thank Warwick Bagg, the DIGAMI 2 Study Group, Peter Gaede and Oluf Borbye Pedersen, John F Service, Alexander Stefanidis, Camilla Hage, and Denise Bonds for answering our requests for information on trials.

This review is also published as a Cochrane review in the Cochrane Database of Systematic Reviews 2011, Issue 6. Cochrane reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the review.

Contributors: BH developed the protocol, was responsible for the searches, selected trials, extracted data, assessed risk of bias of trials, did the data analysis, and developed the final review. SSL developed the protocol, selected trials, and developed the final review. CG developed the protocol, selected trials, advised on statistical methods, and developed the final review. AV developed the protocol, selected trials, and developed the final review. TA developed the protocol, selected trials, extracted data, assessed risk of bias of trials, and developed the final review. CH selected trials, extracted data, assessed risk of bias of trials, analysed data, and developed the final review. JW developed the initial idea for the review, developed the protocol, selected trials, advised on statistical methods, analysed data, and developed the final review. All authors read and approved the final manuscript. BH and JW are the guarantors.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that SSL, AV, and TA have reported equity in Novo Nordisk A/S; SSL and AV have received fees from Novo Nordisk A/S for speaking; TA is employed at Steno Diabetes Center, Gentofte, Denmark; AV and SSL were employed at Steno Diabetes Center at the time the review was written. Steno Diabetes Center is an academic institution owned by Novo Nordisk A/S. CH has been employed at Novo Nordisk after completion of the data extraction.

Ethical approval: Not needed.

Funding: The study was funded by the Copenhagen Trial Unit, Rigshospitalet, Denmark; the Cochrane Metabolic and Endocrine Disorders Group, Germany; and the Copenhagen Insulin and Metformin Therapy Group. The Copenhagen Insulin and Metformin Therapy Group had no role in the design and conduct of the study; the extraction, management, analysis, or interpretation of the data; or the preparation, review, or approval of the manuscript.

Data sharing: No additional data available.

What is already known on this topic

- Patients with type 2 diabetes are at increased risk of macrovascular and microvascular disease
- Uncertainty exists as to whether intensive glycaemic control reduces the risk of death, macrovascular disease, or microvascular disease
- Only a few meta-analyses with a high risk of bias have estimated the effect of intensive glycaemic control on microvascular complications

What this study adds

- Sufficient evidence exists for an absence of a 10% relative risk reduction in all cause mortality with intensive glycaemic control versus conventional glycaemic control in patients with type 2 diabetes
- Insufficient evidence exists for a 10% relative risk reduction in cardiovascular mortality and non-fatal myocardial infarction
- Insufficient evidence exists to support the conclusions that intensive glycaemic control prevents the occurrence of microvascular disease assessed as a composite outcome, retinopathy, or nephropathy
- Sufficient evidence exists that intensive glycaemic control increases the risk of severe hypoglycaemia by 30% compared with conventional glycaemic control

- Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000;321:405-12.
- Khaw KT, Wareham N. Glycated hemoglobin as a marker of cardiovascular risk. *Curr Opin Lipidol* 2006;17:637-43.
- Selvin E, Ning Y, Steffes MW, Bash LD, Klein R, Wong TYAB, et al. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. *Diabetes* 2011;60:298-305.
- Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358:2545-59.
- Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008;358:2560-72.
- Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009;360:129-39.
- Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus—a randomized prospective 6-year study. *Diabetes Res Clin Pract* 1995;28:103-17.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352:837-53.
- Yudkin JS, Richter B, Gale EA. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. *Diabetologia* 2010;53:2079-85.
- American Diabetes Association. Standards of medical care in diabetes—2010. *Diabetes Care* 2010;33(suppl 1):S11-61.
- International Diabetes Federation. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. *Diabet Med* 2006;23:579-93.
- Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetologia* 2009;52:17-30.
- Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Wetterslev J. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2010;4:CD008143.
- Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2011;6:CD008143.
- Higgins JPT, Green S. Cochrane handbook for systematic reviews of intervention 5.0.0. Cochrane Collaboration, 2008 (available from [cochrane-handbook.org](http://www.cochrane-handbook.org)).
- Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med* 2008;358:580-91.
- Guo LX, Pan Q, Wang XX, Li H, Zhang LN, Chi JM, et al. Effect of short term intensive multitherapy on carotid intima-media thickness in patients with newly diagnosed type 2 diabetes mellitus. *Chinese Med J* 2008;121:687-90.
- Yang JM, Guo XH, Yu X. Long-term intensive glycaemic and lipid control ameliorates the carotid intima medial thickness in type 2 diabetes mellitus. *Journal of Peking University Health Sciences* 2007;39:649-52.
- Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. *Eur Heart J* 2005;26:650-61.
- Melidonis A, Stefanidis A, Tournis S, Manoussakis S, Handanis S, Zairis M, et al. The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients. *Clin Cardiol* 2000;23:160-4.
- Stefanidis A, Melidonis A, Tournis S, Zairis M, Handanis S, Beldekos D, et al. Effect of intravenous insulin administration on left ventricular performance during non-ST-elevation acute coronary events in patients with diabetes mellitus. *Am J Cardiol* 2003;91:1237-40.
- Review Manager (RevMan) [computer program]: version 5.0.25. Cochrane Collaboration, 2011.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177-88.
- DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. *Stat Med* 1987;6:341-50.
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539-58.
- Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis—a simulation study. *PLoS One* 2011;6:e25491.
- Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. *J Clin Epidemiol* 2008;61:64-75.
- Higgins JP, Whitehead A, Simmonds M. Sequential methods for random-effects meta-analysis. *Stat Med* 2011;30:903-21.
- Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. *BMC Med Res Methodol* 2009;30:86.
- Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. *J Clin Epidemiol* 2008;61:763-9.
- Barnett AH. Treatment intensification in patients with type 2 diabetes. *Diabetes Obes Metab* 2008;10(suppl 1):iii.
- Brocco E, Velussi M, Cernigoi AM, Abaterusso C, Bruseghin M, Carraro A, et al. Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy. *J Nephrol* 2001;14:461-71.
- Clark R, English M, McNeill G, Newton R. Effect of intravenous infusion of insulin in diabetics with acute myocardial infarction. *BMJ* 1985;291:303-5.
- Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. *J Am Coll Cardiol* 2004;43:8-14.
- Eastman RC, Eastman RC. Is intensive glycaemic control worth the expense? *Cleve Clin J Med* 1997;64:410-3.
- Eibl N, Krugluger W, Streit G, Schratlbauer K, Hopmeier P, Scherthner G. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. *Eur J Clin Invest* 2004;34:205-9.
- Evans RJ, Lane J, Holman RR, Turner RC. Induced basal normoglycemia and altered platelet aggregation in non-insulin-dependent diabetes. *Diabetes Care* 1982;5:433-7.
- Furnay AP, Zerr KJ, Krunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. *Ann Thoracic Surg* 1999;67:352-60.
- Retnakaran R, Yakubovich N, Qi Y, Opsteen C, Zimman B. The response to short-term intensive insulin therapy in type 2 diabetes. *Diabetes Obes Metab* 2010;12:65-71.
- Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. *Diabetes Care* 2004;27:1028-32.
- Leibowitz G, Raizman E, Brezis M, Glaser B, Raz I, Shapira O. Effects of moderate intensity glycaemic control after cardiac surgery. *Ann Thorac Surg* 2010;90:1825-32.
- Barbosa J, Connert J, Fryd D, Sutherland D, Rao V, Anderson R, et al. The Minnesota diabetes complications clinical trial: the first three years. *Acta Diabetologica Latina* 1983;20:165-71.
- Blaha J, Kopecky P, Matias M, Hovorka R, Kunstner J, Kotlak T, et al. Comparison of three protocols for tight glycaemic control in cardiac surgery patients. *Diabetes Care* 2009;32:757-61.
- Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycaemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. *Circulation* 2004;109:1497-502.
- Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenström A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. *Eur Heart J* 1996;17:1337-44.
- Kahn SE, Haffner SM, Vabert G, Herman WH, Lachin JM, Kravitz BG, et al. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from A Diabetes Outcome Progression Trial (ADOPT). *Diabetes Care* 2010;33:177-83.
- Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. *Circulation* 2009;120:2529-40.
- Chan JC, So WY, Yeung CY, Ko GT, Lau IT, Tsang MW, et al. Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. *Diabetes Care* 2009;32:977-82.
- Cleveringa FG, Minkman MH, Gorter KJ, Van den Donk M, Rutten GEHM. Diabetes care protocol: effects on patient-important outcomes. A cluster randomized, non-inferiority trial in primary care. *Diabet Med* 2010;27:442-50.
- Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial in macroVascular Events): a randomised controlled trial. *Lancet* 2005;366:1279-89.
- Du JL, Liu JF, Men LL, Yao JJ, Sun LP, Sun GH, et al. Effects of five-year intensive multifactorial intervention on the serum amyloid A and macroangiopathy in patients with short-duration type 2 diabetes mellitus. *Chinese Med J* 2009;122:2560-6.
- Hanefeld M, Koehler C, Hoffmann C, Wilhelm K, Kamke W, Gerstein H. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early type 2 diabetes. *Diabet Med* 2010;27:175-80.

- 53 Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycaemic control over 3 years (UK Prospective Diabetes Study 44). *Diabetes Care* 1999;22:960-4.
- 54 Johansen OE, Gullestad L, Blaasaas KG, Orvik E, Birkeland KI. Effects of structured hospital-based care compared with standard care for type 2 diabetes—the Asker and Baerum Cardiovascular Diabetes Study, a randomized trial. *Diabet Med* 2007;24:1019-27.
- 55 Joss N. Intensive medical management in type 2 diabetes and nephropathy: renal consequences [abstract no: SU-P0860]. *J Am Soc Nephrol* 2002;13:646A.
- 56 Menard J, Payette H, Baillargeon JP, Maheux P, Lepage S, Tessier D, et al. Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. *CMAJ* 2005;173:1457-66.
- 57 Olivarius NF, Beck-Nielsen H, Andreasen AH, Horder M, Pedersen PA. Randomised controlled trial of structured personal care of type 2 diabetes mellitus. *BMJ* 2001;323:970-5.
- 58 Platt GA, Anderson RM, Brooks MM, Songer T, Siminerio LM, Korytkowski MM, et al. 3-year follow-up of clinical and behavioral improvements following a multifaceted diabetes care intervention: results of a randomized controlled trial. *Diabetes Educ* 2010;36:301-9.
- 59 Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. *Diabetes Care* 2009;32:381-6.
- 60 Shi Q, Ostwald SK, Wang S. Improving glycaemic control self-efficacy and glycaemic control behaviour in Chinese patients with type 2 diabetes mellitus: randomised controlled trial. *J Clin Nurs* 2010;19:398-404.
- 61 Van Bruggen R, Gorter K, Stolk R, Klungel O, Rutten G. Clinical inertia in general practice: widespread and related to the outcome of diabetes care. *Fam Pract* 2009;26:428-36.
- 62 Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. *Lancet* 1999;353:617-22.
- 63 Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* 2003;348:383-93.
- 64 Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. *Diabetes Care* 2008;31:1510-5.
- 65 Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. *Eur Heart J* 2008;29:166-76.
- 66 Stefanidis A, Melidonis A, Tournis S, Zairis M, Handanis S, Olympios C, et al. Intensive insulin treatment reduces transient ischaemic episodes during acute coronary events in diabetic patients. *Acta Cardiol* 2002;57:357-64.
- 67 Action to Control Cardiovascular Risk in Diabetes Study. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Protocol. 2009. www.accordtrial.org/public/documents/Protocol%20All%20Chapters.pdf.
- 68 Bonds DE, Kurashige EM, Bergenstal R, Brillion D, Domanski M, Felicetta JV, et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol* 2007;99:80i-9i.
- 69 Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, et al. The association between symptomatic, severe hypoglycemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. *BMJ* 2010;340:b4909.
- 70 Buse JB, Bigler JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. *Am J Cardiol* 2007;99:21i-33i.
- 71 Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. *N Engl J Med* 2010;363:233-44.
- 72 Cushman WC, Evans GW, Byington RP, Goff DCJ, Grimm RHJ, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med* 2010;362:1575-85.
- 73 Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med* 2010;362:1563-74.
- 74 Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet* 2010;376:419-30.
- 75 Beulens JW, Patel A, Vingerling JR, Cruickshank JK, Hughes AD, Stanton A, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. *Diabetologia* 2009;52:2027-36.
- 76 Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. *Diabetes Care* 2009;32:2068-74.
- 77 Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. *N Engl J Med* 2010;363:1410-8.
- 78 ADVANCE Collaborative Group. ADVANCE. 2011. www.advance-trial.com.
- 79 Bagg W, Ferri C, Desideri G, Gamble G, Ockelford P, Braatvedt GD. The influences of obesity and glycaemic control on endothelial activation in patients with type 2 diabetes. *J Clin Endocrinol Metab* 2001;86:5491-7.
- 80 Bagg W. Cardiac and endothelial function is unaffected by short-term intensive glycaemic control in patients with type-2 diabetes mellitus [abstract]. *Int Med J* 2001;31:A1.
- 81 Bagg W, Plank LD, Gamble G, Drury PL, Sharpe N, Braatvedt GD. The effects of intensive glycaemic control on body composition in patients with type 2 diabetes. *Diabetes Obes Metab* 2001;3:410-6.
- 82 Bagg W, Whalley GA, Gamble G, Drury PL, Sharpe N, Braatvedt GD, et al. Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. *Intern Med J* 2001;31:322-8.
- 83 Becker A, van der Does FEE, van Hinsbergh VWM, Heine RJ, Bouter LM, Stehouwer CDA. Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, von Willebrand factor and (pro)insulin. *Neth J Med* 2003;61:129-36.
- 84 Van der Does FE, de Neeling JN, Snoek FJ, Grootenhuys PA, Kostense PJ, Bouter LM, et al. Randomized study of two different target levels of glycaemic control within the acceptable range in type 2 diabetes: effects on well-being at 1 year. *Diabetes Care* 1998;21:2085-93.
- 85 Lapina YV, Filatov DN, Mareev VY, Yu O, Bolotina MG, Shestakova MV, et al. Effect of strict glycaemic control on clinical state and course of the disease in patients with chronic heart failure and type II diabetes mellitus: results of the REMBO (Rational Effective Multicomponent therapy in the struggle against diabetes mellitus in patients with congestive heart failure) Study. *Kardiologiya* 2008;48:17-27.
- 86 Lu WH, Shi BY, Zhang XT, Wei DG, Liu WD, Duan PZ. Significance of intensive glycaemic control on early diabetic nephropathy patients with microalbuminuria. *Academic Journal of Xi'an Jiaotong University* 2010;22:135-8.
- 87 Service FJ, Daube JR, O'Brien PC, Zimmerman BR, Swanson CJ, Brennan MD, et al. Effect of blood glucose control on peripheral nerve function in diabetic patients. *Mayo Clin Proc* 1983;58:283-9.
- 88 Knatterud GL, Klimt CR, Levin ME, Jacobson ME, Goldner MG. Effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes: VII. Mortality and selected nonfatal events with insulin treatment. *JAMA* 1978;240:37-42.
- 89 University Group Diabetes Program. A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes: I. Design, methods and baseline results. *Diabetes* 1970;19:747-72.
- 90 University Group Diabetes Program. A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes: II. Mortality results. *Diabetes* 1970;19:789-830.
- 91 University Group Diabetes Program. Effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes: VIII. Evaluation of insulin therapy: final report. *Diabetes* 1982;31(suppl 5):1-81.
- 92 Hage C, Norhammar A, Grip L, Malmberg K, Sarkar N, Svane B, et al. Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study. *Diab Vasc Dis Res* 2009;6:71-9.
- 93 Yngen M, Norhammar A, Hjemdahl P, Wallén NH. Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. *Diab Vasc Dis Res* 2006;3:52-6.
- 94 Jaber LA, Halapy H, Fernet M, Tummalaipalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. *Ann Pharmacother* 1996;30:238-43.
- 95 Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. *Diabetes Care* 2000;23(suppl 2):B21-9.
- 96 Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. *Diabetes Res Clin Pract* 2000;48:201-10.
- 97 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008;359:1577-89.
- 98 Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C, et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS 51). *Diabetologia* 2001;44:298-304.
- 99 Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR, et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). *Diabetologia* 2005;48:868-77.
- 100 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998;352:854-65.
- 101 UK Prospective Diabetes Study (UKPDS) Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). *Diabetes Care* 1999;22:1125-36.
- 102 UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study (UKPDS) VIII: study design, progress and performance. *Diabetologia* 1991;34:877-90.
- 103 Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. *Arch Intern Med* 1997;157:181-8.
- 104 Levin SR, Coburn JW, Abraira C, Henderson WG, Colwell JA, Emanuele NV, et al. Effect of intensive glycaemic control on microalbuminuria in type 2 diabetes. *Diabetes Care* 2000;23:1478-85.
- 105 Emanuele N, Klein R, Abraira C, Colwell J, Comstock J, Henderson WG, et al. Evaluations of retinopathy in the VA cooperative study on glycaemic control and complications in type II diabetes (VA CSDM). *Diabetes Care* 1996;19:1375-81.
- 106 Abraira C, Emanuele N, Colwell J, Henderson W, Comstock J, Levin S, et al. Glycaemic control and complications in type II diabetes: design of a feasibility trial. *Diabetes Care* 1992;15:1560-71.
- 107 Pitale S, Kernan-Schroeder D, Emanuele N, Sawin C, Sacks J, Abraira C, et al. Health-related quality of life in the VA feasibility study on glycaemic control and complications in type 2 diabetes mellitus. *J Diabetes Complications* 2005;19:207-11.
- 108 Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes: VA feasibility study on glycaemic control and complications (VA CSDM). *Diabetes Care* 1998;21:574-9.
- 109 Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, et al. Veterans Affairs Cooperative Study on glycaemic control and complications in type II diabetes (VA CSDM): results of the feasibility trial. *Diabetes Care* 1995;18:1113-23.
- 110 Abraira C, Duckworth W, McCarren M, Emanuele N, Arca D, Reda D, et al. Design of the cooperative study on glycaemic control and complications in diabetes mellitus type 2 Veterans Affairs diabetes trial. *J Diabetes Complications* 2003;17:314-22.
- 111 Abraira C, Duckworth WC, Moritz T. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. *Diabetes Obes Metab* 2009;11:150-6.
- 112 Fermi Paradox. www.crystalinks.com/fermiparadox.html.
- 113 Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. *BMJ* 2011;343:d4169.
- 114 Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. *Diabetologia* 2009;52:2288-98.
- 115 Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycaemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. *Nutr Metab Cardiovasc Dis* 2009;19:604-12.
- 116 Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *Lancet* 2009;373:1765-72.
- 117 Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. *Ann Intern Med* 2009;151:394-403.

- 118 Wu H, Xu MJ, Zou DJ, Han QJ, Hu X. Intensive glycemic control and macrovascular events in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. *Chinese Med J* 2010;123:2908-13.
- 119 Marso SP, Kennedy KF, House JA, McGuire DK. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. *Diab Vasc Dis Res* 2010;7:119-30.
- 120 Zhang CY, Sun AJ, Zhang SN, Wu CN, Fu MQ, Xia G, et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis. *Ann Med* 2010;42:305-15.
- 121 Ma J, Yang W, Fang N, Zhu W, Wei M. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis. *Nutr Metab Cardiovasc Dis* 2009;19:596-603.
- 122 Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DCJ, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. *N Engl J Med* 2011;364:818-28.

Accepted: 22 September 2011

Cite this as: [BMJ 2011;343:d6898](#)

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: <http://creativecommons.org/licenses/by-nc/2.0/> and <http://creativecommons.org/licenses/by-nc/2.0/legalcode>.

Tables

Table 1 | Excluded trials

Trial	Reason for exclusion
ADOPT 2010 ⁴⁶	No predefined differences in glycaemic target
Barbosa et al 1983 ⁴²	Did not include participants with type 2 diabetes
BARI 2D 2009 ⁴⁷	No predefined differences in glycaemic target
Barnett et al 2008 ³¹	Not a randomised clinical trial
Blaha et al 2009 ⁴³	Patients with type 2 diabetes reported together with patients without diabetes
Brocco et al 2001 ³²	Not a randomised clinical trial
Chan et al 2009 ⁴⁸	No predefined differences in glycaemic target
Clark et al 1985 ³³	Not a randomised clinical trial
Cleveringa et al 2010 ⁴⁹	No predefined differences in glycaemic target
Corpus et al 2004 ³⁴	Not a randomised clinical trial
DIGAMI 1996 ⁴⁵	Patients with type 1 diabetes and type 2 diabetes reported together
DIGAMI 2 2005 ^{19 65}	Intensive glycaemic control applied as a part of acute intervention
Du et al 2009 ⁵¹	No predefined differences in glycaemic target
Eastman et al 1997 ³⁵	Not a randomised clinical trial
Eibl et al 2004 ³⁶	Not a randomised clinical trial
Evans et al 1982 ³⁷	Not a randomised clinical trial
Furnary et al 1999 ³⁸	Not a randomised clinical trial
Guo et al 2008 ¹⁷	Intensive glycaemic control applied as part of multimodal intervention
Hanefeld et al 2010 ⁵²	No predefined differences in glycaemic target
HEART 2D 2009 ⁵⁹	Randomised into two groups targeting same HbA _{1c} with different strategies (basal v prandial)
Johansen et al 2007 ²⁴	No predefined differences in glycaemic target
Joss et al 2002 ⁵⁵	No predefined differences in glycaemic target
Lazar et al 2004 ⁴⁴	Patients with type 1 diabetes and type 2 diabetes reported together
Leibowitz et al 2010 ⁴¹	Not a randomised clinical trial
Melidonis et al 2000 ³⁰	Intensive glycaemic control applied as part of acute intervention
Menard et al 2005 ⁵⁶	No predefined differences in glycaemic target
Olivarius et al 2001 ⁵⁷	No predefined differences in glycaemic target
Piatt et al 2010 ⁵⁸	No predefined differences in glycaemic target
PROactive et al 2005 ⁵⁰	No predefined differences in glycaemic target
Retnakaran et al 2010 ³⁹	Not a randomised clinical trial
Ryan et al 2004 ⁴⁰	Not a randomised clinical trial
Shi et al 2010 ⁵⁰	No predefined differences in glycaemic target
Stefanidis et al 2003 ^{21 66}	Intensive glycaemic control applied as part of acute intervention
Steno 2 2008 ^{16 62-64}	Intensive glycaemic control applied as part of multimodal intervention
UKPDS-44 1999 ⁵³	No predefined differences in glycaemic target
Van Bruggen et al 2009 ⁶¹	No predefined differences in glycaemic target
Yang et al 2007 ¹⁸	Intensive glycaemic control applied as part of multimodal intervention

ADOPT=A Diabetes Outcome Progression Trial; BARI 2D=Bypass Angioplasty Revascularization Investigation 2 Diabetes; DIGAMI=Diabetes Insulin-Glucose in Acute Myocardial Infarction; HbA_{1c}=glycated haemoglobin A_{1c}; HEART 2D=Hyperglycaemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus; PROactive=PROspective pioglitAzone Clinical Trial In macroVascular Events; UKPDS=United Kingdom Prospective Diabetes Study.

Table 2| Key characteristics of included trials

Trial	Location	Design	No of intensive/conventional (total) participants	Length of follow-up*	Intensive glycaemic control	Conventional glycaemic control
ACCORD 2008 ^{4 67-74}	77 centres; USA and Canada	Randomised, 2×2 factorial design	5128/5123 (10 251)	3.5 years	HbA _{1c} <6%; fasting SMBG <5.6 mmol/L or 2 hour blood glucose <7.8 mmol/L	HbA _{1c} 7.0-7.9%; fasting SMBG >5.0 mmol/L
ADVANCE 2008 ⁷⁵⁻⁷⁸	215 centres; 20 countries	Randomised, factorial design	5571/5569 (11 140)	5.0 years	HbA _{1c} ≤6.5%	Glycaemic target of HbA _{1c} defined from local guidelines
Bagg et al 2001 ⁷⁹⁻⁸²	1 centre; New Zealand	Randomised	21/22 (43)	20 weeks	HbA _{1c} <7%; before meal capillary glucose 4-7 mmol/L; 2 hour blood glucose <10 mmol/L	Avoid symptoms of hyperglycaemia and fortnightly fasting capillary glucose test >17 mmol/L
Becker et al 2003 ^{83 84}	1 centre; Netherlands	Randomised	106/108 (231)	22 months	Fasting capillary blood glucose <6.5 mmol/L	Fasting capillary blood glucose <8.5 mmol/L
IDA 2009 ^{92 93}	2 centres; Sweden	Randomised	51/51 (102)	6 months and 3 weeks	HbA _{1c} <6.5%; fasting blood glucose 5-7 mmol/L; before meal <10 mmol/L	Standard treatment
Jaber et al 1996 ⁹⁴	1 centre; USA	Randomised	23/22 (45)	4 months	Fasting blood glucose ≤6.6 mmol/L; 2 hour postprandial glucose <10 mmol/L, or to reach maximum daily dose of sulfonylurea	Not defined
Kumamoto 2000 ^{7 95 96}	1 centre; Japan	Randomised	55/55 (110)	10 years	HbA _{1c} <7.0%; fasting blood glucose <140 mg/dL; 2 hour postprandial glucose <200 mg/dL; mean amplitude of glycaemic excursions <100 mg/dL	Fasting blood glucose close to <140 mg/dL without symptoms of hyperglycaemia or hypoglycaemia
Lu et al 2010 ⁸⁶	1 centre; China	Randomised	21/20 (41)	12 weeks	Fasting blood glucose <6.1 mmol/L; postprandial 2 hour glucose <7.8 mmol/L	Fasting blood glucose <7.0 mmol/L; postprandial 2 hour glucose <10.0 mmol/L
REMBO 2008 ⁸⁵	1 centre; Russia	Randomised	41/40 (81)	12 months	HbA _{1c} <7% in participants receiving sulfonylurea; HbA _{1c} <6.5% in participants receiving insulin	Not specified
Service et al 1983 ⁸⁷	1 centre; USA	Randomised	10/10 (20)	1.75 years	HbA _{1c} to normal range, and to maintain 80 minute postprandial plasma glucose <8.3 mmol/L	Eliminate symptoms, but not to degree to reduce 80 minute postprandial plasma glucose below 150 mg/dL
UGDP 1978 ⁸⁸⁻⁹¹	12 centres; USA	Randomised	204/210 (414)	12 years	Maintain blood glucose in normal range (defined as fasting blood glucose <110 mg/100 mL, blood glucose <210 mg/100 mL 1 hour after ingestion of 50 g glucose and 1 and 1.5 hours after morning insulin injection)	Minimise likelihood of hypoglycaemic reactions without reducing insulin dose to pharmacologically inactive amounts
UKPDS 1998 ^{1 8 97-102}	23 centres, UK	Randomised (some participants randomised to blood pressure arm)	3071/1138 (4209)	UKPDS 33 10.0 years; UKPDS 34 10.7 years	Fasting blood glucose <6 mmol/L in insulin treated patients; pre-meal glucose 4-7 mmol/L	Fasting blood glucose <15 mmol/L without symptoms of hyperglycaemia
VA CSDM 1995 ¹⁰³⁻¹⁰⁹	5 centres; USA	Randomised	75/78 (153)	27 months	Maintain mean HbA _{1c} <7.5%; treatment adjusted with home blood glucose monitoring, aiming at fasting blood glucose 4.48-6.44 mmol/L and other pre-prandial levels ≤7.28 mmol/L	Avoid excessive hyperglycaemia or symptoms of excessive glucosuria, ketonuria, or hypoglycaemia (alert HbA _{1c} <12.9%)
VADT 2009 ^{6 110 111}	20 centres; USA	Randomised	892/899 (1791)	5.6 years	HbA _{1c} ≤6%; goal for HbA _{1c} was absolute reduction of 1.5 percentage points in intensive therapy group, compared with conventional intervention group	Wellbeing, avoidance of deterioration of HbA _{1c} , keeping levels at 8-9%, and preventing symptoms of glycosuria, hypoglycaemia, and ketonuria

ACCORD=Action to Control Cardiovascular Risk in Diabetes Study; ADVANCE=Action in Diabetes and Vascular disease—PreterAx and DiamicroN MR Controlled Evaluation; HbA_{1c}=glycated haemoglobin A_{1c}; IDA=Insulin Diabetes Angioplasty; REMBO=Rational Effective Multicomponent Therapy in the Struggle Against Diabetes Mellitus in Patients With COngestive Heart Failure; SMBG=self monitoring of blood glucose; UGDP=University Group Diabetes Program; UKPDS=United Kingdom Prospective Diabetes Study; VACSDM=Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus; VADT=Veterans Affairs Diabetes Trial.

Table 2 (continued)

Trial	Location	Design	No of intensive/conventional (total) participants	Length of follow-up*	Intensive glycaemic control	Conventional glycaemic control
*Mean or median.						

Table 3| Key characteristics of participants

Trial	Age (years)*	Duration of disease at baseline (years)*	HbA _{1c} at baseline (%)*	Fasting blood glucose at baseline (mmol/L)*†	Previous cardiovascular disease, intensive/conventional (No)
ACCORD 2008 ^{4 67-74}	62.2	10	8.3	9.8	1826/1783
ADVANCE 2008 ⁷⁵⁻⁷⁸	66.0	8.0	7.5	8.5	1794/1796
Bagg et al 2001 ⁷⁹⁻⁸²	55.9	6.9	10.7	13.5	2/2
Becker et al 2003 ^{83 84}	63.3	3.3	NR	9.6	21/23
IDA 2009 ^{92 93}	64.0	6.5	6.5	7.2	51/51
Jaber et al 1996 ⁹⁴	62.4	6.5	11.9‡	12.0	NR
Kumamoto 2000 ^{7 95 96}	49.6	8.6	9.2	9.2	0/0
Lu et al 2010 ⁸⁶	59.5	8.2	9.0	9.3	NR
REMBO 2008 ⁸⁵	64	5.5	7.2	6.6	41/40
Service et al 1983 ⁸⁷	50.7	0.5	11.4	8.7	NR
UGDP 1978 ⁸⁸⁻⁹¹	52.7§	Newly diagnosed	NR	7.9	7/16¶
UKPDS 1998 ^{1 8 97-102}	53.2**	Newly diagnosed	7.1**	8.1**	77††
VA CSDM 1995 ¹⁰³⁻¹⁰⁹	60.1	7.8	9.4	11.9	31/27
VADT 2009 ^{6 110 111}	60.4	11.5	9.4	10.9	355/368

ACCORD=Action to Control Cardiovascular Risk in Diabetes Study; ADVANCE=Action in Diabetes and Vascular disease—PreterAx and DiamicroN MR Controlled Evaluation; IDA=Insulin Diabetes Angioplasty; NR=not reported; REMBO=Rational Effective Multicomponent Therapy in the Struggle Against Diabetes Mellitus in Patients With Congestive Heart Failure; UGDP=University Group Diabetes Program; UKPDS=United Kingdom Prospective Diabetes Study; VACSDM=Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus; VADT=Veterans Affairs Diabetes Trial.

*Mean or median.

†Converted from mg/dL to mmol/L by dividing by 18.

‡Described as glycated haemoglobin.

§Age reported for all treatment groups together.

¶Previous cardiovascular disease reported as history of angina.

**Number for baseline characteristics taken from UKPDS 33.

††Number taken from meta-analysis by Turnbull et al.¹¹⁴

Table 4| Risk of bias assessments of included trials

Trial	Sequence generation	Allocation concealment	Blinding	Incomplete outcome data	Selective outcome reporting	Free from other bias
ACCORD 2008 ^{4 67-74}	Adequate	Adequate	Adequate	Unclear	Adequate	Inadequate
ADVANCE 2008 ⁷⁵⁻⁷⁸	Adequate	Adequate	Adequate	Adequate	Adequate	Inadequate
Bagg et al 2001 ⁷⁹⁻⁸²	Unclear	Unclear	Adequate	Adequate	Adequate	Adequate
Becker et al 2003 ^{83 84}	Unclear	Unclear	Unclear	Unclear	Adequate	Adequate
IDA 2009 ^{92 93}	Adequate	Adequate	Adequate	Adequate	Adequate	Inadequate
Jaber et al 1996 ⁹⁴	Unclear	Unclear	Unclear	Adequate	Adequate	Inadequate
Kumamoto 2000 ^{7 95 96}	Unclear	Unclear	Unclear	Adequate	Unclear	Inadequate
Lu et al 2010 ⁸⁶	Unclear	Unclear	Unclear	Unclear	Adequate	Adequate
REMBO 2008 ⁸⁵	Unclear	Unclear	Unclear	Adequate	Adequate	Unclear
Service et al 1983 ⁸⁷	Adequate	Unclear	Adequate	Adequate	Adequate	Adequate
UGDP 1978 ⁸⁸⁻⁹¹	Adequate	Adequate	Adequate	Adequate	Adequate	Adequate
UKPDS 1998 ^{1 8 97-102}	Adequate	Adequate	Adequate	Adequate	Adequate	Inadequate
VA CSDM 1995 ¹⁰³⁻¹⁰⁹	Unclear	Unclear	Adequate	Adequate	Adequate	Inadequate
VADT 2009 ^{6 110 111}	Adequate	Adequate	Adequate	Adequate	Adequate	Inadequate

ACCORD=Action to Control Cardiovascular Risk in Diabetes Study; ADVANCE=Action in Diabetes and Vascular disease—PreterAx and DiamicroN MR Controlled Evaluation; IDA=Insulin Diabetes Angioplasty; REMBO=Rational Effective Multicomponent Therapy in the Struggle Against Diabetes Mellitus in Patients With Congestive Heart Failure; UGDP=University Group Diabetes Program; UKPDS=United Kingdom Prospective Diabetes Study; VACSDM=Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus; VADT=Veterans Affairs Diabetes Trial.

Figures

Fig 1 Flow diagram of identification of randomised trials for inclusion

Fig 2 Forest plot for all cause mortality

Fig 3 Trial sequential analysis of all cause mortality. Heterogeneity adjusted required information size of 46 677 participants calculated on basis of proportion of mortality of 8.4% in conventional glucose control group, relative risk reduction of 10%, $\alpha=5\%$, $\beta=20\%$, and $I^2=30\%$. Actually accrued No of participants was 28 149, 60% of required information size. Dashed red cumulative Z curve does not cross solid blue trial sequential monitoring boundaries for benefit or harm, but boundaries for futility (blue inner wedge boundaries) are crossed. Horizontal dotted green lines illustrate traditional level of statistical significance ($P=0.05$)

Fig 4 Forest plot for cardiovascular mortality

Fig 5 Trial sequential analysis for cardiovascular mortality. Heterogeneity adjusted required information size of 129 468 participants calculated on basis of proportion of cardiovascular mortality of 4.1% in conventional glucose control group, relative risk reduction of 10%, $\alpha=5\%$, $\beta=20\%$, and $I^2=46\%$. Actually accrued No of participants was 28 149, 22% of required information size. Dashed red cumulative Z curve does not cross solid blue trial sequential monitoring boundaries for benefit or harm. Horizontal dotted green lines illustrate the traditional level of statistical significance ($P=0.05$)

Fig 6 Forest plot for non-fatal myocardial infarction

Fig 7 Trial sequential analysis for non-fatal myocardial infarction. Heterogeneity adjusted required information size of 63 446 participants calculated on basis of proportion of non-fatal myocardial infarction of 4.5% in conventional glucose control group, relative risk reduction of 10%, $\alpha=5\%$, $\beta=20\%$, and $I^2=0\%$. Actually accrued No of participants was 27 958, 44% of required information size. Dashed red cumulative Z curve does not cross solid blue trial sequential monitoring boundaries for benefit or harm. Horizontal dotted green lines illustrate the traditional level of statistical significance ($P=0.05$)

Fig 8 Forest plot for composite microvascular outcome

Fig 9 Trial sequential analysis for composite microvascular outcome. Heterogeneity corrected required information size of 43 703 participants calculated on basis of proportion of composite microvascular outcome of 11.1% in conventional glucose control group, relative risk reduction of 10%, $\alpha=5\%$, $\beta=20\%$, and $I^2=45\%$. Dashed red cumulative Z curve does not cross solid blue trial sequential monitoring boundaries for benefit or harm. Horizontal dotted green lines illustrate the traditional level of statistical significance ($P=0.05$)

Fig 10 Forest plot for retinopathy

Fig 11 Trial sequential analysis for retinopathy. Heterogeneity corrected required information size of 43 960 participants calculated on basis of proportion of retinopathy of 14.3% in conventional glucose control group, relative risk reduction of 10%, $\alpha=5\%$, $\beta=20\%$, and $I^2=59\%$. Actually accrued No of participants was 10 793, 25% of required information size. Dashed red cumulative Z curve does not cross solid blue trial sequential monitoring boundaries for benefit or harm. Horizontal dotted green lines illustrate the traditional level of statistical significance ($P=0.05$)

Fig 12 Forest plot for nephropathy

Fig 13 Forest plot for severe hypoglycaemia

Fig 14 Trial sequential analysis for severe hypoglycaemia. Heterogeneity adjusted required information size of 36 937 participants calculated on basis of proportion of severe hypoglycaemia of 2.9% in conventional glucose control group, relative risk reduction of 30%, $\alpha=5\%$, $\beta=20\%$, and $I^2=73\%$. Cumulative Z curve crosses trial sequential monitoring boundary, showing sufficient evidence reached for 30% increase in relative risk with targeted intensive glycaemic control. Horizontal dotted green lines illustrate the traditional level of statistical significance ($P=0.05$)